NYSE:SNN Smith & Nephew SNATS (SNN) Stock Price, News & Analysis $36.04 +0.55 (+1.54%) Closing price 08/7/2025 03:59 PM EasternExtended Trading$36.08 +0.03 (+0.08%) As of 04:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Smith & Nephew SNATS Stock (NYSE:SNN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Smith & Nephew SNATS alerts:Sign Up Key Stats Today's Range$35.81▼$36.5650-Day Range$28.53▼$36.0552-Week Range$23.69▼$36.56Volume1.43 million shsAverage Volume1.14 million shsMarket Capitalization$15.79 billionP/E Ratio16.69Dividend Yield2.47%Price Target$28.00Consensus RatingHold Company Overview Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom. Read More Smith & Nephew SNATS Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreSNN MarketRank™: Smith & Nephew SNATS scored higher than 49% of companies evaluated by MarketBeat, and ranked 544th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingSmith & Nephew SNATS has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageSmith & Nephew SNATS has received no research coverage in the past 90 days.Read more about Smith & Nephew SNATS's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth18.34% Earnings GrowthEarnings for Smith & Nephew SNATS are expected to grow by 18.34% in the coming year, from $1.69 to $2.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Smith & Nephew SNATS is 16.69, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Smith & Nephew SNATS is 16.69, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.87.Price to Earnings Growth RatioSmith & Nephew SNATS has a PEG Ratio of 1.08. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioSmith & Nephew SNATS has a P/B Ratio of 2.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.62% of the float of Smith & Nephew SNATS has been sold short.Short Interest Ratio / Days to CoverSmith & Nephew SNATS has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Smith & Nephew SNATS has recently increased by 4.62%, indicating that investor sentiment is decreasing. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldSmith & Nephew SNATS pays a meaningful dividend of 2.52%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthSmith & Nephew SNATS does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Smith & Nephew SNATS is 41.20%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Smith & Nephew SNATS will have a dividend payout ratio of 44.50% next year. This indicates that Smith & Nephew SNATS will be able to sustain or increase its dividend.Read more about Smith & Nephew SNATS's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.62% of the float of Smith & Nephew SNATS has been sold short.Short Interest Ratio / Days to CoverSmith & Nephew SNATS has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Smith & Nephew SNATS has recently increased by 4.62%, indicating that investor sentiment is decreasing. News and Social Media3.1 / 5News Sentiment0.65 News SentimentSmith & Nephew SNATS has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Smith & Nephew SNATS this week, compared to 4 articles on an average week.MarketBeat Follows1 people have added Smith & Nephew SNATS to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Smith & Nephew SNATS insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.00% of the stock of Smith & Nephew SNATS is held by insiders.Percentage Held by InstitutionsOnly 25.64% of the stock of Smith & Nephew SNATS is held by institutions.Read more about Smith & Nephew SNATS's insider trading history. Receive SNN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Smith & Nephew SNATS and its competitors with MarketBeat's FREE daily newsletter. Email Address SNN Stock News HeadlinesSmith & Nephew: Doing Better And Still Offers ValueAugust 7 at 12:08 PM | seekingalpha.comSmith & Nephew plc 2025 Q2 - Results - Earnings Call PresentationAugust 5 at 10:06 AM | seekingalpha.comAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation. | Paradigm Press (Ad)Smith & Nephew: Investors Looking To Continued Innovation And Margin Growth In Q2 EarningsJuly 29, 2025 | seekingalpha.comSmith+Nephew expands market-leading fixation strength of Q-FIX™ All-Suture Anchor portfolio with new knotless optionJuly 7, 2025 | globenewswire.comSmith+Nephew's new TRIGEN™ MAX Tibia Nailing System brings ‘next-level nailing' to trauma surgeons repairing tibial fracturesJune 24, 2025 | globenewswire.comAjay Dhankhar joins Smith+Nephew as Chief Corporate Development & Strategy OfficerJune 23, 2025 | globenewswire.comSmith+Nephew and Standard Health partner on first Orthopaedic Ambulatory Surgery Centre in the UKJune 18, 2025 | globenewswire.comSee More Headlines SNN Stock Analysis - Frequently Asked Questions How have SNN shares performed this year? Smith & Nephew SNATS's stock was trading at $24.58 at the start of the year. Since then, SNN stock has increased by 46.6% and is now trading at $36.0450. How were Smith & Nephew SNATS's earnings last quarter? Smith & Nephew SNATS, Inc. (NYSE:SNN) posted its quarterly earnings results on Monday, November, 17th. The medical equipment provider reported $0.98 earnings per share for the quarter, topping analysts' consensus estimates of $0.39 by $0.59. Who are Smith & Nephew SNATS's major shareholders? Top institutional investors of Smith & Nephew SNATS include Bank of Montreal Can (0.78%), Scharf Investments LLC (0.48%), Envestnet Asset Management Inc. (0.12%) and Oliver Luxxe Assets LLC (0.04%). How do I buy shares of Smith & Nephew SNATS? Shares of SNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Smith & Nephew SNATS own? Based on aggregate information from My MarketBeat watchlists, some other companies that Smith & Nephew SNATS investors own include JPMorgan Chase & Co. (JPM), Johnson & Johnson (JNJ), PepsiCo (PEP), Taiwan Semiconductor Manufacturing (TSM), McDonald's (MCD), Sanofi (SNY) and Alibaba Group (BABA). Company Calendar Last Earnings11/17/2014Record date for 5/28 Dividend3/28/2025Ex-Dividend for 5/28 Dividend3/28/2025Dividend Payable5/28/2025Today8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED PRODUCTS Sub-IndustryMedical Equipment Current SymbolNYSE:SNN CIK845982 Webwww.smith-nephew.com Phone441923477100Fax44-20-7930-3353Employees17,349Year Founded1856Price Target and Rating Average Price Target for Smith & Nephew SNATS$28.00 High Price Target$28.00 Low Price Target$28.00 Potential Upside/Downside-22.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio16.69 Forward P/E Ratio21.33 P/E Growth1.08Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.62 Current Ratio2.89 Quick Ratio1.33 Sales & Book Value Annual Sales$5.94 billion Price / Sales2.66 Cash Flow$3.21 per share Price / Cash Flow11.24 Book Value$12.04 per share Price / Book2.99Miscellaneous Outstanding Shares437,978,000Free Float433,598,000Market Cap$15.79 billion OptionableOptionable Beta0.68 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NYSE:SNN) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Smith & Nephew SNATS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Smith & Nephew SNATS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.